B2Gold Corp. (NYSEMKT: BTG) announced fourth quarter and full-year 2014 gold production and revenue as well as production and cash cost guidance for 2015. Record annual consolidated gold production of 384,003 ounces (or 391,162 ounces including 7,159 ounces of pre-commercial production from Otjikoto in December). On Wednesday shares of B2Gold Corp. (NYSEMKT: BTG) closed at $2.20.
Delta Air Lines, Inc. (NYSE:DAL) posted its quarterly earnings results on Tuesday. The company reported $0.78 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.72 by $0.06. The company had revenue of $9.65 billion for the quarter, compared to the consensus estimate of $9.57 billion. During the same quarter last year, the company posted $0.65 earnings per share. Delta Air Lines’s revenue was up 6.3% compared to the same quarter last year. On Wednesday shares of Delta Air Lines, Inc. (NYSE:DAL) closed at $49.18. Company’s sales growth for last 5 years was 10.70% and EPS growth for next 5 years is recorded as 18.98%.
On 7 January Rush Enterprises, Inc. (NASDAQ:RUSHB) announced that it has appointed Dr. Kennon Guglielmo and William “Bill” Cary to serve on its Board of Directors. On last trading day Rush Enterprises, Inc. (NASDAQ:RUSHB) moved up 1.78% to close at $25.17. Its volatility for the week is 2.08% while volatility for the month is 2.07%. Rush Enterprises, Inc. (NASDAQ:RUSHB) monthly performance is -10.33%.
Shares of UIL Holdings Corporation (NYSE:UIL) have earned a consensus recommendation of “Buy” from the six ratings firms that are covering the stock. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $42.75. UIL Holdings Corporation (NYSE:UIL) has 0.20% insider ownership while its institutional ownership stands at 68.20%. In last trading activity company’s stock closed at $46.46.
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) and Intrexon and are striking a deal with the University of Texas’ MD Anderson Cancer Center. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) in last trading activity moved down -9.97% to close at $6.86. Company weekly performance is 19.51% while its quarterly performance stands at 177.73%. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) is -27.79% away from its 52 week high.